Perhaps this implies tumours in patients with LGI1 antibodies largely reflect the age-matched background rate, rather than a distinct immune mechanism, although a paucity of tumours classically associated with paraneoplastic neurological syndromes may limit our interpretation. This evidence concerns the gene LGI1 and paraneoplastic neurologic syndrome.